To test the ability of GSK256073 to block niacin-induced flushing when GSK256073 and niacin are co-administered as single doses to HVTs.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
24
single dosing for 4 to 5 sessions
GSK Investigational Site
Baltimore, Maryland, United States
Intensity of reported flushing - visual analogue scale; self reported assessment of flushing
Time frame: up to 8 hours post dose
Safety and tolerability of GSK256073A and immediate release niacin
Time frame: up to 36 hours post dose
Standard and Secondary pharmacokinetic endpoints of interest
Time frame: up to 36 hours post dose
Pharmacodynamic response
Time frame: up to 36 hours post dose
Pharmacodynamic response
Time frame: up to 24 hours post dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.